Press Detail





News: Biotest AG: Publication of the offer document on the voluntary public tender for Biotest AG by CREAT Group

News: Biotest AG / Key word(s): Offer
Biotest AG: Publication of the offer document on the voluntary public tender
for Biotest AG by CREAT Group

18.05.2017 / 11:45
The issuer is solely responsible for the content of this announcement.



PRESS RELEASE

Publication of the offer document on the voluntary public tender for Biotest
AG by CREAT Group

- Offer document reaffirms the offer announced on April 7, 2017

- The Management Board and the Supervisory Board welcome and support the
offer

- The Management Board and the Supervisory Board will carefully review the
offer document and issue a reasoned opinion pursuant to Section 27 WpÜG.

- The acceptance period will run from May 18, 2017, and is expected to end
on June 15, 2017


Dreieich, 18 May 2017. Tiancheng (Germany) Pharmaceutical Holdings AG, the
acquiring company of CREAT Group, today published the offer document on the
voluntary public tender for all outstanding shares of Biotest AG. As
announced on April 7, 2017, Tiancheng (Germany) Pharmaceutical Holdings AG
is offering 28.50 Euro per Biotest ordinary share and 19.00 Euro per Biotest
preference share.

The Management Board and the Supervisory Board will review the offer
document carefully, bearing in mind the Company's best interests, and issue
a reasoned opinion on the offer pursuant to Section 27 of the German
Securities Acquisition and Transfer Act (WpÜG). Both boards welcome and
support the offer.

Today's publication of the offer document marks the start of the acceptance
period, which is expected to end on June 15, 2017.


About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and markets
immunoglobulins, coagulation factors and albumins based on human blood
plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus which
are produced by recombinant technologies. Biotest has more than 2,500
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich,
Stuttgart

Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and assumes
no obligation to do so.




18.05.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de



Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange



End of News DGAP News Service


575179 18.05.2017